Anti Cancer Injection

Approx. Rs 12,000 / VialGet Latest Price

Product Details:

Octreotide LAR 30mg (Long-Acting Release) is a prescription depot injection (powder & solvent for suspension) used to treat acromegaly, functional gastro-entero-pancreatic neuroendocrine tumors (carcinoid tumors), and to manage symptoms like severe diarrhea and flushing.

Approx. Rs 1,100 / VialGet Latest Price

Product Details:

Bortezomib 2 mg injection is a proteasome inhibitor used to treat multiple myeloma and mantle-cell lymphoma by blocking protein breakdown to kill cancer cells.

Approx. Rs 1,900 / VialGet Latest Price

Product Details:

Decitabine Lyophilized Injection (50 mg50 mg50 mg or 30 mg30 mg30 mg vials) is a prescription antineoplastic agent used to treat myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). 

Approx. Rs 7,800 / PieceGet Latest Price

Product Details:

Leuprolide acetate 11.25 mg for injection (often as Lupride Depot, Lupron Depot) is a long-acting GnRH agonist used for hormone-sensitive conditions like prostate cancer, endometriosis, uterine fibroids, and central precocious puberty.

Approx. Rs 27,000 / VialGet Latest Price

Product Details:

Nivolumab (brand name Tishtha) is an intravenous immunotherapy drug used to treat various advanced cancers, including melanoma, lung, kidney, liver, and Hodgkin lymphoma. As a PD-1 checkpoint inhibitor, it blocks a protein on T-cells to enable the immune system to recognize and kill cancer cells. Common side effects include fatigue, musculoskeletal pain, rash, and diarrhea. Key Details About Nivolumab: Uses: It is used for melanoma, non-small cell lung cancer, renal cell cancer, Hodgkin's lymphoma, squamous cell cancer of the head and neck, liver cancer, and others. Mechanism of Action: It is a monoclonal antibody that binds to the PD-1 receptor on T-cells, preventing cancer cells from suppressing the immune system, thereby activating a T-cell-mediated immune response. Side Effects: Common adverse reactions include fatigue, rash, musculoskeletal pain, diarrhea, nausea, fever, decreased appetite, and potential immune-mediated issues affecting organs like the liver or thyroid. Administration: It is given via intravenous infusion (typically over 30–60 minutes) in a clinical setting. Success Rates: While efficacy varies by cancer type and stage, it has shown significant potential in extending survival in advanced cancers.